�A raw,
pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI
38 study showed patients wHO took prasugrel for acute coronary syndromes
(ACS) managed with an artery-opening procedure known as percutaneous
coronary thrombosis intervention (PCI) and had survived their first cardiovascular
event and then suffered a subsequent event, were 35 pct less likely to
get a perennial event (composite endpoint of heart plan of attack, stroke or
cardiovascular death) than those who took clopidogrel (10.8% vs. 15.4%;
P=0.016). These data appear as a special boost access on-line publication
from the European Heart Journal.
The return of subsequent events assessment was part of the larger
TRITON-TIMI 38 visitation, the elemental measure of which showed that prasugrel
taken with aspirin decreased the congenator risk of the combined endpoint of
cardiovascular death, non-fatal g with the
United States Securities and Exchange Commission and Daiichi Sankyo's
filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake
no duty to update advanced statements.
Plavix(R)/Iscover(R) ar registered trademarks of Sanofi-Synthelabo
Inc.
References
(1) Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in
Patients with Acute Coronary Syndromes. New England Journal of Medicine.
November 2007; 357: 2001-15.
(2) American Heart Association. Heart Disease and Stroke Statistics -
2008 Update. Dallas, TX. American Heart Association. (Pg. 14)
(3) British Heart Foundation Health Promotion Research Group. European
Cardiovascular Disease Statistics 2008,
http://www.ehnheart.org/content/ItemPublication.asp?docid=7069&level0=1500&level1=2157, Accessed April 24 2008.
(4) WebMD Medical Reference in Collaboration with the Cleveland Clinic.
Heart Disease: Coronary Artery Disease. June 2004.
Eli Lilly and Company
http://www.lilly.com
View drug information on PLAVIX.
More info
